Type Mutant Stock; Targeted Mutation; Additional information on Genetically Engineered and Mutant Mice. Visit our online Nomenclature tutorial. Species laboratory mouse Donating Investigator Yaacov Barak, University of Pittsburgh Description
These mice express tTA (tetracycline regulated transactivator) and a tetO-driven Flag-tagged Pparg from the endogenous Pparg locus. A fusion transcript (including the 5' portion of Pparg, IRES and tTA (AF1-IRES-tTA)), a Flag-Pparg transcript and a wildtype transcript are detected by Northem blot analysis of white adipose tissue from heterozygotes. The fusion transcript of AF1-IRES-tTA is also detected in brown adipose tissue. Expression of tTA is detected in adipose tissue by Western blot analysis. No Flag-PPARG1 protein was detected in adipose tissue. Weak expression of tTA and the Flag-Pparg transcript is observed in placenta and liver. Endogenous PPARG2 protein is reduced in adipose tissues of heterozygotes. Heterozygotes exhibit "buffalo humps" (swollen interscapular fat pads swollen by hypertrophy and unilocular lipid deposition in mutant brown adipocytes), absence of subcutaneous adipocytes, reduced gonadal white adipose tissue, irregularly residual adipocyte shape and size, and fibrotic white adipose tissue stroma with leukocytic infiltration of the adipose tissue. Although, mutant mice have hyperinsulinemia, pancreatic islet hyperplasia, severe glucose intolerance, and hepatomegaly, they do not develop steatosis or type II diabetes. Prepubertal male heterozygotes exhibit hyperglycemia which normalizes with age. Treatment with doxycycline prevents this phenotype when administered starting at midgestation. A 6 week doxycycline treatment administered to pubertal heterozygotes reverses most of the phenotype, except the reduction in white adipose tissue. Mice that are homozygous for the targeted mutation are not viable. This mutant mouse strain may be useful in studies of lipodystrophy.Development
The Ldi cassette, containing IRES sequence, tTA (tetracycline regulated transactivator), PGK-neo, polyA, and a flag-tagged Pparg (peroxisome proliferator activated receptor gamma) cDNA sequence, was used to replace exon 2. The construct was electroporated into 129S4/SvJae derived J1 embryonic stem (ES) cells. Correctly targeted ES cells were injected into recipient blastocysts. The resulting chimeric animals were crossed to 129S1/SvImJ mice. The Donating Investigator maintained the strain as a heterozygote because of the homozygous lethal phenotype.
| Control | ||
|---|---|---|
| Wild-type from the colony | ||
| 002448 129S1/SvImJ | ||
| Considerations for Choosing Controls | ||
Strains carrying other alleles of Pparg
004584 B6.129-Ppargtm2Rev/J 006142 B6.129S4-Ppargtm1Rev/J 008227 B6.129S4-Ppargtm3Yba/J View Strains carrying other alleles of Pparg (3 strains)
Strains carrying other alleles of tTA
016198 129S6.Cg-Tg(Camk2a-tTA)1Mmay/JlwsJ 011008 B6.129P2(Cg)-Gt(ROSA)26Sortm1(tTA)Roos/J 009602 B6.129S4(Cg)-Kcnn2tm2Jpad/J 009603 B6.129S4-Kcnn3tm1Jpad/J 008227 B6.129S4-Ppargtm3Yba/J 012359 B6.Cg-Pvalbtm1.1(tTA2)Hze/J 016868 B6.Cg-Ssttm1.2(tTA2)Hze/J 007004 B6.Cg-Tg(Camk2a-tTA)1Mmay/DboJ 003563 B6.Cg-Tg(Cebpb-tTA)5Bjd/J 003767 B6.Cg-Tg(Eno2tTA)5021Nes/J 003763 B6.Cg-Tg(Eno2tTA)5030Nes/J 018306 B6.Cg-Tg(Fos-tTA,Fos-EGFP*)1Mmay/J 005964 B6.Cg-Tg(GFAP-tTA)110Pop/J 002618 B6.Cg-Tg(MMTVtTA)1Mam/J 008284 B6.Cg-Tg(Scg2-tTA)1Jt/J 006361 B6.Cg-Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/J 017722 B6.Cg-Tg(Tal1-tTA)19Dgt/J 017754 B6;129-Omptm1(tTA)Gogo/J 007585 B6;129S4-Npytm2Rpa/J 002709 B6;C3-Tg(TettTALuc)1Dgs/J 003010 B6;CBA-Tg(Camk2a-tTA)1Mmay/J 008344 B6;DBA-Tg(Fos-tTA,Fos-EGFP*)1Mmay Tg(tetO-lacZ,tTA*)1Mmay/J 010573 B6;SJL-Tg(Prl-tTA)6-5Jek/J 008082 B6;SJL-Tg(Tagln-tTA)1Mrab Tg(tetO-Mcpt1)1Mrab/J 008603 C.129P2(B6)-Gt(ROSA)26Sortm1(tTA)Roos/J 010712 C57BL/6-Tg(Camk2a-tTA)1Stl/J 013585 FVB-Tg(Cdh5-tTA)D5Lbjn/J 005625 FVB-Tg(Pcp2-tTA)3Horr/J 003170 FVB.Cg-Tg(Myh6-tTA)6Smbf/J 006209 FVB.Cg-Tg(Tal1-tTA)19Dgt/J 005942 FVB/N-Tg(Pf4-tTA/VP16)42Kra/J 004937 NOD.Cg-Tg(Ins2-tTA)1Doi/DoiJ 006999 STOCK Dbttm1Geh Tg(Cebpb-tTA)5Bjd Tg(tetO-DBT)A1Geh/J 008335 STOCK Foxa2tm1.1(rtTa)Moon/J 008600 STOCK Gt(ROSA)26Sortm1(tTA)Roos/J 005701 STOCK Pdx1tm1Macd/J 014092 STOCK Tg(ACTB-tTA2,-MAPT/lacZ)1Luo/J 003271 STOCK Tg(CMV-tTA)3Bjd/J 015838 STOCK Tg(Camk2a-tTA)1Mmay Tg(tetO-ABL1*P242E*P249E)CPdav/J 018124 STOCK Tg(Prnp-tTA)F959Sbp/J 009606 STOCK Tg(Six2-EGFP/cre)1Amc/J 003275 STOCK Tg(tetL)1Bjd/J 003274 STOCK Tg(tetNZL)2Bjd/J View Strains carrying other alleles of tTA (43 strains)
Strains carrying other alleles of tetO
016176 B6(Cg)-Tg(tetO-Per2)2Jt/J 009602 B6.129S4(Cg)-Kcnn2tm2Jpad/J 009603 B6.129S4-Kcnn3tm1Jpad/J 017983 B6.Cg-Col1a1tm9(tetO-Dnmt3b*)Jae Gt(ROSA)26Sortm1(rtTA*M2)Jae/J 014588 B6.Cg-Gt(ROSA)26Sortm1(rtTA*M2)Jae Col1A1tm6(tetO-MSI2)Jae/J 014648 B6.Cg-Gt(ROSA)26Sortm37(H1/tetO-RNAi:Taz)Arte/ZkhuJ 006361 B6.Cg-Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/J 016998 B6.Cg-Tg(TetO-Axin1,EGFP)TA6Cos/J 003762 B6.Cg-Tg(tetFosb)4468Nes/J 007051 B6.Cg-Tg(tetO-APPSwInd)102Dbo/Mmjax 007052 B6.Cg-Tg(tetO-APPSwInd)107Dbo/Mmjax 007049 B6.Cg-Tg(tetO-APPSwInd)885Dbo/Mmjax 007618 B6.Cg-Tg(tetO-Arntl)1Jt/J 017555 B6.Cg-Tg(tetO-CALY)5Cber/J 008277 B6.Cg-Tg(tetO-Clockm1Jt)CL57Jt/J 008468 B6.Cg-Tg(tetO-DTA)1Gfi/J 017791 B6.Cg-Tg(tetO-Hamp)2181Nca/J 009344 B6.Cg-Tg(tetO-Ifng)184Pop/J 009136 B6.Cg-Tg(tetO-Kcnj2,lacZ)1Gogo/J 013583 B6.Cg-Tg(tetO-LRRK2)C7874Cai/J 020652 B6.Cg-Tg(tetO-Mif)279Aren/J 017331 B6.Cg-Tg(tetO-Ppp3ca*)11255Kndl/J 017332 B6.Cg-Tg(tetO-Ppp3ca*)13967Kndl/J 017330 B6.Cg-Tg(tetO-TAg*)175Kndl/J 006234 B6.Cg-Tg(tetO-cre)1Jaw/J 005738 B6.FVB-Tg(tetO-EGFP,-Tgfbr2)8Mcle/J 006911 B6;129-Gt(ROSA)26Sortm1(rtTA*M2)Jae Col1a1tm2(tetO-Pou5f1)Jae/J 011001 B6;129S4-Col1a1tm1(tetO-Pou5f1,-Klf4,-Sox2,-Myc)Hoch/J 016836 B6;129S4-Gt(ROSA)26Sortm1(rtTA*M2)Jae Col1a1tm7(tetO-HIST1H2BJ/GFP)Jae/J 012433 B6;C3-Tg(ACTA1-rtTA,tetO-cre)102Monk/J 002709 B6;C3-Tg(TettTALuc)1Dgs/J 016841 B6;C3-Tg(tetO-TARDBP)12Vle/J 014650 B6;C3-Tg(tetO-TARDBP*)4Vle/J 012450 B6;D2-Tg(tetO-SNCA)1Cai/J 008344 B6;DBA-Tg(Fos-tTA,Fos-EGFP*)1Mmay Tg(tetO-lacZ,tTA*)1Mmay/J 008082 B6;SJL-Tg(Tagln-tTA)1Mrab Tg(tetO-Mcpt1)1Mrab/J 010575 B6;SJL-Tg(tetO-Egfr*)2-9Jek/J 010577 B6;SJL-Tg(tetO-Erbb2*)8-4Jek/J 002621 B6;SJL-Tg(tetop-lacZ)2Mam/J 006004 B6C3-Tg(tetO-APPSwInd)885Dbo/Mmjax 016976 B6C3-Tg(tetO-SNCA*A53T)33Vle/J 018913 B6N.Cg-Tg(tetO-GFP,-lacZ)G3Rsp/J 006244 C.Cg-Tg(tetO-cre)1Jaw/J 017719 C3HeB/FeJ-Tg(tetO-TAg)1Efr/J 017955 C57BL/6-Tg(Gfap-rtTA,tetO-MAOB,-lacZ)1Jkan/J 005706 C57BL/6-Tg(tetO-CDK5R1/GFP)337Lht/J 006618 C57BL/6-Tg(tetO-COX8A/EYFP)1Ksn/J 017613 C57BL/6-Tg(tetO-Cdkn1b)1Scpr/J 013729 C57BL/6-Tg(tetO-EDN1,-lacZ)9Mhus/J 010713 C57BL/6-Tg(tetO-GFP/tetX)5696Stl/J 013728 C57BL/6-Tg(tetO-NOS2,-lacZ)240iMhus/J 016181 C57BL/6-Tg(tetO-Nr1d1)1Schb/J 008278 C57BL/6J-Tg(tetO-Clock)1Jt/J 021065 FVB(C)-Tg(tetO-Npc1/YFP)1Mps/J 017542 FVB-Tg(Myh6/tetO-ATP2B4)1Jmol/J 016571 FVB-Tg(Myh6/tetO-Gata6)2Jmol/J 014155 FVB-Tg(Myh6/tetO-Itpr1)22.3Jmol/J 014153 FVB-Tg(Myh6/tetO-Itpr2)3.11Jmol/J 014154 FVB-Tg(Myh6/tetO-Itpr2)4.9Jmol/J 012684 FVB-Tg(Myh6/tetO-POSTN)22.1Jmol/J 010580 FVB-Tg(Myh6/tetO-PRKCA*)1Jmk/J 013156 FVB-Tg(tetO-CDK5R1*)1Vln/J 013777 FVB-Tg(tetO-Cacna1g)1Jmol/J 013778 FVB-Tg(tetO-Cacnb2)1Jmol/J 013779 FVB-Tg(tetO-Cacnb2)2Jmol/J 013780 FVB-Tg(tetO-Cib1)1Jmol/J 010578 FVB-Tg(tetO-Dusp6)1Jmol/J 017333 FVB-Tg(tetO-Gnai2*,-lacZ)382Kndl/J 008685 FVB-Tg(tetO-Kdr*)4377.5Rwng/J 015815 FVB-Tg(tetO-MAPT*P301L)#Kha/JlwsJ 008695 FVB-Tg(tetO-MET)23Rwng/J 012387 FVB-Tg(tetO-Ppargc1a)1Dpk/J 012385 FVB-Tg(tetO-Ppargc1b)7Dpk/J 006439 FVB-Tg(tetO/CMV-KRAS*G12C)9.1Msmi/J 008244 FVB.Cg-Tg(tetO-cre)1Jaw/J 012459 FVB/N-Tg(Myh6*/tetO-Capn1)L2Gwd/J 005941 FVB/N-Tg(tetO-Aurkb,lacZ)41Kra/J 006202 FVB/N-Tg(tetO-BCR/ABL1)2Dgt/J 014547 FVB/N-Tg(tetO-Fasl)BDepa/J 019376 FVB/N-Tg(tetO-MYC)36aBop/J 003315 FVB/N-Tg(tetORo1-lacZ)3Conk/J 005076 NOD.Cg-Tg(tetO-EGFP/FADD)1Doi/DoiJ 006999 STOCK Dbttm1Geh Tg(Cebpb-tTA)5Bjd Tg(tetO-DBT)A1Geh/J 011004 STOCK Gt(ROSA)26Sortm1(rtTA*M2)Jae Col1a1tm3(tetO-Pou5f1,-Sox2,-Klf4,-Myc)Jae/J 011011 STOCK Gt(ROSA)26Sortm1(rtTA*M2)Jae Col1a1tm4(tetO-Pou5f1,-Sox2,-Klf4,-Myc)Jae/J 011013 STOCK Gt(ROSA)26Sortm1(rtTA*M2)Jae Col1a1tm5(tetO-Pou5f1,-Klf4,-Myc)Jae/J 018999 STOCK Gt(ROSA)26Sortm1(tTA,tetO-Mir155)Fjsl/J 017596 STOCK Gt(ROSA)26Sortm1.1(rtTA,EGFP)Nagy Smn1tm1Msd Tg(SMN2)89Ahmb Tg(SMN2*delta7)4299Ahmb Tg(tetO-SMN2,-luc)#aAhmb/J 017597 STOCK Gt(ROSA)26Sortm1.1(rtTA,EGFP)Nagy Smn1tm1Msd Tg(SMN2)89Ahmb Tg(SMN2*delta7)4299Ahmb Tg(tetO-SMN2,-luc)#bAhmb/J 015838 STOCK Tg(Camk2a-tTA)1Mmay Tg(tetO-ABL1*P242E*P249E)CPdav/J 008755 STOCK Tg(Ins2-rtTA)2Efr Tg(teto-DTA)1Gfi/J 012477 STOCK Tg(Myh6*/tetO-GCaMP2)1Mik/J 016572 STOCK Tg(Myh6/tetO-Gata4)1Jmol/J 014544 STOCK Tg(tetO-ABL1*P242E*P249E)CPdav/J 014093 STOCK Tg(tetO-CHRM3*)1Blr/J 008790 STOCK Tg(tetO-DISC1*)1001Plet/J 008168 STOCK Tg(tetO-DTA)1Gfi/J 017755 STOCK Tg(tetO-GCAMP2)12iRyu/J 005104 STOCK Tg(tetO-HIST1H2BJ/GFP)47Efu/J 005699 STOCK Tg(tetO-Ipf1,EGFP)956.6Macd/J 005728 STOCK Tg(tetO-Ipf1,lacZ)958.1Macd/J 012441 STOCK Tg(tetO-LRRK2*G2019S)E3Cai/J 017599 STOCK Tg(tetO-SMN2,-luc)#aAhmb/J 017600 STOCK Tg(tetO-SMN2,-luc)#bAhmb/J 012442 STOCK Tg(tetO-SNCA*A53T)E2Cai/J 006224 STOCK Tg(tetO-cre)1Jaw/J 017906 STOCK Tg(tetO-hop/EGFP,-COP4/mCherry)6Kftnk/J 012345 STOCK Tg(tetO-tdTomato,-Syp/EGFP*)1.1Luo/J 012449 STOCK Tg(teto-LRRK2)C7874Cai/J View Strains carrying other alleles of tetO (109 strains)
Tet Expression Systems
View Related Disease (OMIM) Terms
Related Disease (OMIM) Terms provided by MGI
- Model with phenotypic similarity to human disease where etiologies involve orthologs. Human genes are associated with this disease. Orthologs of those genes appear in the mouse genotype(s).
Lipodystrophy, Familial Partial, Type 3; FPLD3- Model with phenotypic similarity to human disease where etiologies are distinct. Human genes are associated with this disease. Orthologs of these genes do not appear in the mouse genotype(s).
Lipodystrophy, Congenital Generalized, Type 2; CGL2
- Potential model based on gene homology relationships. Phenotypic similarity to the human disease has not been tested. Carotid Intimal Medial Thickness 1 (PPARG)
Diabetes Mellitus, Noninsulin-Dependent; NIDDM (PPARG)
Obesity (PPARG)
View Mammalian Phenotype Terms
Mammalian Phenotype Terms provided by MGI
assigned by genotype
The following phenotype information may relate to a genetic background differing from this JAX® Mice strain.
Ppargtm2Yba/Pparg+
involves: 129S1/SvImJ * C57BL/6
- reproductive system phenotype
- reduced fertility
- mice exhibit poor fecundity after introgression onto a C57BL/6 background (MGI Ref ID J:125992)
- adipose tissue phenotype
- *normal* adipose tissue phenotype
- despite the development of dyslipidemia and severe insulin resistance, mice do not develop steatosis or type 2 diabetes (MGI Ref ID J:125992)
- abnormal brown adipose tissue morphology
- abnormal white adipose tissue morphology
- fibrotic white adipose tissue stroma is filled with fragmented lipid droplets and leukocytes (MGI Ref ID J:125992)
- remaining adipocytes have irregular shapes and range in size from overtly hypertrophic to minuscule cells (MGI Ref ID J:125992)
- however, defects were prevented by midgestational administration of doxycycline but adipocyte size does not revert following treatment with doxycycline (MGI Ref ID J:125992)
- abnormal white fat cell morphology
- remaining adipocytes have irregular shapes (MGI Ref ID J:125992)
- abnormal white fat cell size
- remaining adipocytes range in size from overtly hypertrophic to minuscule cells (MGI Ref ID J:125992)
- absent subcutaneous adipose tissue
- mice lack subcutaneous adipocytes (MGI Ref ID J:125992)
- decreased gonadal fat pad weight
- increased interscapular fat pad weight
- mice exhibit 'buffalo humps' comprised of swollen interscapular fat pads due to hypertrophy and unilocular lipid deposition in mutant brown adipocytes (MGI Ref ID J:125992)
- however, defects can be prevented by midgestational administration of doxycycline and reverted by a 6 week treatment with doxycycline (MGI Ref ID J:125992)
- homeostasis/metabolism phenotype
- *normal* homeostasis/metabolism phenotype
- despite the development of dyslipidemia and severe insulin resistance, mice do not develop steatosis or type 2 diabetes (MGI Ref ID J:125992)
- hyperglycemia
- impaired glucose tolerance
- increased circulating cholesterol level
- increased circulating free fatty acid level
- increased circulating insulin level
- increased circulating triglyceride level
- insulin resistance (MGI Ref ID J:125992)
- endocrine/exocrine gland phenotype
- pancreas hyperplasia
- mice as old as 12 to 18 months exhibit hyperplasia with intact and insulin-laden pancreatic islets with hyperinsulinemia and normoglycemia (MGI Ref ID J:125992)
- pancreatic islet hyperplasia
- liver/biliary system phenotype
- abnormal hepatocyte morphology
- mice exhibit hepatocyte hypertrophy and vacuolization (MGI Ref ID J:125992)
- enlarged liver
- integument phenotype
- absent subcutaneous adipose tissue
- mice lack subcutaneous adipocytes (MGI Ref ID J:125992)
View Research Applications
Research Applications
This mouse can be used to support research in many areas including:
Developmental Biology Research
Embryonic Lethality (Homozygous)
Metabolism Research
Lipid Metabolism
Research Tools
Metabolism Research
Tet Expression Systems
tTA/rtTA Expressing Strains
tTA/rtTA Responsive Strains
| Allele Symbol | Ppargtm2Yba | ||
|---|---|---|---|
| Allele Name | targeted mutation 2, Yaacob Barak | ||
| Allele Type | Targeted (knock-in) | ||
| Common Name(s) | Ppargldi; | ||
| Mutation Made By | Yaacov Barak, University of Pittsburgh | ||
| Strain of Origin | 129S4/SvJae | ||
| ES Cell Line Name | J1 | ||
| ES Cell Line Strain | 129S4/SvJae | ||
| Site of Expression | Expression of tTA from the endogenous Pparg locus is detected in adipose tissue. | ||
| Expressed Gene | tetO, tet operator, | ||
| Expressed Gene | tTA, tetracycline-controlled transactivator, E. coli | ||
| The tetracycline-resistance gene (TetR), arose from chemically mutated Escherichia coli genome which was screened for tetracycline dependence (Gossen and Bujard, 1992). TetR was fused at the C-terminus with the viral co-activator, virion protein 16 of the herpes simplex virus (VP-16). The tetracycline-inhibitable transcription factor is a component of a bigenic system that allows doxycycline (a tetracycline analog) regulatable expression of genes that are under the direction of the tetracycline responsive promoter (TetOp)promoter. | |||
| Molecular Note | Exon 2 was replaced with an Idi cassette that contains an IRES-tTA, neo, poly-adenylation signal, TetO and flag-tagged cDNA. While expression is modest in adipose tissue, it is poor in the liver and placenta. [MGI Ref ID J:125992] | ||
| Gene Symbol and Name | Pparg, peroxisome proliferator activated receptor gamma | ||
| Chromosome | 6 | ||
| Gene Common Name(s) | CIMT1; GLM1; NR1C3; PPAR-gamma; PPARG1; PPARG2; PPARgamma; PPARgamma2; Ppar-gamma2; | ||
Genotyping Protocols
Ppargtm2Yba, Melt Curve Analysis
Ppargtm2Yba, Standard PCR
Helpful Links
Genotyping resources and troubleshooting
Kim S; Huang LW; Snow KJ; Ablamunits V; Hasham MG; Young TH; Paulk AC; Richardson JE; Affourtit JP; Shalom-Barak T; Bult CJ; Barak Y. 2007. A mouse model of conditional lipodystrophy. Proc Natl Acad Sci U S A 104(42):16627-32. [PubMed: 17921248] [MGI Ref ID J:125992]
Ppargtm2Yba relatedArck P; Toth B; Pestka A; Jeschke U. 2010. Nuclear Receptors of the Peroxisome Proliferator-Activated Receptor (PPAR) Family in Gestational Diabetes: From Animal Models to Clinical Trials. Biol Reprod 83(2):168-76. [PubMed: 20427759] [MGI Ref ID J:161967]
Animal Health Reports
Production of mice from cryopreserved embryos or sperm occurs in a maximum barrier room, G200.Colony Maintenance
Breeding & Husbandry When maintaining a live colony, these mice can be bred as heterozygotes. Homozygotes are not viable. The Donating Investigator maintained the strain by crossing heterozygous males, between 3 and 5 months of age, to wildtype 129S1/SvImJ females. This strain has a problematic fecundity with only about half of the heterozygous male animals between 3 and 5 months of age reproducing.
| Pricing for USA, Canada and Mexico shipping destinations |
|
Cryopreserved Mice - Ready for Recovery
Animals Provided
Price (US dollars $) Cryorecovery* $1980.00 At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.
Standard Supply
Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.
Supply Notes
- Cryorecovery - Standard.
Progeny testing is not required.
The average number of mice provided from recovery of our cryopreserved strains is 10. The total number of animals provided, their gender and genotype will vary. We will fulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 11 and 14 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.Cryorecovery to establish a Dedicated Supply for greater quantities of mice.
Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).
| Pricing for International shipping destinations |
|
Cryopreserved Mice - Ready for Recovery
Animals Provided
Price (US dollars $) Cryorecovery* $2574.00 At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.
Standard Supply
Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.
Supply Notes
- Cryorecovery - Standard.
Progeny testing is not required.
The average number of mice provided from recovery of our cryopreserved strains is 10. The total number of animals provided, their gender and genotype will vary. We will fulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 11 and 14 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.Cryorecovery to establish a Dedicated Supply for greater quantities of mice.
Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).
|
|
Cryopreserved. Ready for recovery. Please refer to pricing and supply notes on the strain data sheet for further information.
| Control | ||
|---|---|---|
| Wild-type from the colony | ||
| 002448 129S1/SvImJ | ||
| Considerations for Choosing Controls | ||
| Control Pricing Information for Genetically Engineered Mutant Strains. | ||
For Licensing and Use Restrictions view the link(s) below:
- Use of MICE by companies or for-profit entities requires a license prior to shipping.
| phone: | 207-288-6470 |
| fax: | 207-288-6655 |
MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.
In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.
In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.
MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.
The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.
Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.